Oral GLP‑1 Pill Approved

Semaglutide is a hormone-mimicking drug that helps people feel full and eat less. The Food and Drug Administration has now cleared a tablet version of Wegovy, making it the first oral glucagon-like peptide 1, or GLP-1, medicine approved in the U.S. for chronic weight management. (fda.gov) The new label covers adults with obesity, or adults with overweight plus at least one weight-related condition, alongside a reduced-calorie diet and more physical activity. The same tablet label also includes a cardiovascular indication for adults with established heart disease and obesity or overweight. (fda.gov) The approval follows Phase 3 OASIS 4 data in adults without diabetes testing oral semaglutide 25 milligrams once a day. In the New England Journal of Medicine, investigators reported a 13.6% mean body-weight reduction with the pill, versus 2.2% with placebo, and an estimated treatment difference of 11.4 percentage points. (nejm.org) A separate earlier OASIS trial tested a higher 50-milligram daily dose and found a 15.1% mean weight reduction at 68 weeks, versus 2.4% with placebo, showing that oral semaglutide could approach the weight-loss range seen with injectable semaglutide. (thelancet.com) Novo Nordisk said in its 2025 annual report that the pill had already launched in the U.S. and called it the first approved once-daily oral GLP-1 for weight management. The company also said the product gives patients another option besides weekly injections. (novonordisk.com) That timing matters because demand for semaglutide has turned obesity treatment into a mass-market category, while many patients and clinicians have been looking for a version that does not require a shot. Novo Nordisk’s U.S. site has since folded the pill into broader access and pricing programs for FDA-approved semaglutide medicines. (novonordisk-us.com) The safety profile still looks like the rest of the GLP-1 class: mostly stomach-related side effects that rise during dose escalation. In OASIS 4, gastrointestinal adverse events were reported in 74.0% of patients on oral semaglutide and 42.2% on placebo. (nejm.org) The Food and Drug Administration label carries the same boxed warning already familiar from semaglutide injections: thyroid C-cell tumors in rodents, with use contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The label also warns about pancreatitis, gallbladder problems, kidney injury from dehydration, and severe gastrointestinal reactions. (fda.gov) Hair loss has become a frequent patient concern online, but the bigger clinical discussion has centered on what kind of weight is being lost. Researchers and physicians have been tracking lean-mass changes, protein intake, and resistance training as more people stay on GLP-1 drugs for longer periods. (fda.gov) (acc.org) For patients, the practical change is simple: the best-known obesity drug class now comes as a daily pill as well as a weekly injection. For doctors, the next question is whether easier dosing expands treatment without changing the tradeoffs that already define semaglutide. (fda.gov)